Predictors of improved OS were lenvatinib dose reduction (HR 0.38, 95% CI 0.23–0.63, p < 0.01) or withholding therapy (HR 0.44, 95% CI 0.24–0.82, p < 0.01), a higher baseline albumin (HR 0.89, 95% CI 0.85–0.93, p < 0.01) and the development of hypertension (HR 0.56, 95% CI 0.34–0.94, p = 0.02). This evidence concerns the gene ALB and hypertensive disorder.